<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423992</url>
  </required_header>
  <id_info>
    <org_study_id>Xuanwu hospital</org_study_id>
    <nct_id>NCT03423992</nct_id>
  </id_info>
  <brief_title>Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Efficacy of Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Based on the Expression of Tumor Specific/Associated Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Mario Biotech Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Senlang BIotech Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing HuiNengAn Biotech Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell&#xD;
      (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor&#xD;
      with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent&#xD;
      malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII,&#xD;
      IL13Rα2, Her-2, EphA2, CD133, GD2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events attributed to the administration of the chimeric antigen receptor T cells</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the toxicity profile of the chimeric antigen receptor T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical activity of chimeric antigen receptor T cells</measure>
    <time_frame>28 days</time_frame>
    <description>the number of infused chimeric antigen receptor T cells;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glioma</condition>
  <condition>Malignant Glioma of Brain</condition>
  <condition>Recurrence Tumor</condition>
  <arm_group>
    <arm_group_label>Biological: Chimeric antigen receptor T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>chimeric antigen receptor T cells</intervention_name>
    <description>chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively</description>
    <arm_group_label>Biological: Chimeric antigen receptor T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary informed consent for entry of trial;&#xD;
&#xD;
          -  Age greater than 18 years, and less than 70 years;&#xD;
&#xD;
          -  Pathologically confirmed recurrent malignant gliomas;&#xD;
&#xD;
          -  Tumor cells from resected tissue must be available for antigen testing (EGFRvIII,&#xD;
             IL13Rα2, Her-2, CD133, EphA2, GD2) and at least one of the targets should be tested&#xD;
             positively by immunohistochemistry study;&#xD;
&#xD;
          -  If the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for&#xD;
             at least 5 days prior to apheresis.&#xD;
&#xD;
          -  Patients must have a Karnofsky performance status of greater than or equal to 70.&#xD;
&#xD;
          -  Life expectancy greater than 3 months;&#xD;
&#xD;
          -  Participants with adequate organ function as measured by:&#xD;
&#xD;
               1. White blood count greater than or equal to 2500/mm^3; platelets greater than or&#xD;
                  equal to 100,000/mm^3, hemoglobin greater than or equal to 10.0 g/dL; without&#xD;
                  transfusion or growth factor support&#xD;
&#xD;
               2. Aspartate transaminase (AST), Alanine transaminase (ALT), gamma glutamyl&#xD;
                  transpeptidase (GGT), lactic acid dehydrogenase (LDH), alkaline phosphatase&#xD;
                  within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0&#xD;
                  mg/dL&#xD;
&#xD;
               3. Serum creatinine less than or equal to 1.5 x upper limit of normal&#xD;
&#xD;
               4. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT)&#xD;
                  have to be within normal limits, unless the patient has been therapeutically&#xD;
                  anti-coagulated for previous venous thrombosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects of reproductive potential who are pregnant or lactating;&#xD;
&#xD;
          -  Previous treatment with any gene therapy products or other form immunotherapy;&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Active or latent chronic hepatitis B [detectable hepatitis B surface antigen (HBsAg)]&#xD;
             or active hepatitis C (positive serology [hepatitis C virus Ab]) infection.&#xD;
&#xD;
          -  HIV infection;&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study product excipients (human serum&#xD;
             albumin, Dimethyl sulfoxide, and Dextran 40);&#xD;
&#xD;
          -  Currently enrolled in other clinical trials;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Cheng, M.D.</last_name>
      <phone>8610-83192683</phone>
      <email>chengye@xwhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Qingtang Lin, M.D., Ph.D.</last_name>
      <phone>8610-83192683</phone>
      <email>linqingtang@xwhosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Qingtang Lin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Ling, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ye Cheng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Qingtang Lin</investigator_full_name>
    <investigator_title>Associate Professor, Department of Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

